BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Poulsen PB, Johnsen SP, Hansen ML, Brandes A, Husted S, Harboe L, Dybro L. Setting priorities in the health care sector - the case of oral anticoagulants in nonvalvular atrial fibrillation in Denmark. Clinicoecon Outcomes Res 2017;9:617-27. [PMID: 29066923 DOI: 10.2147/CEOR.S145813] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Tan SK, Looi WL, Yeo HY. Estimation of direct medical costs of warfarin, dabigatran and rivaroxaban treatments in non‐valvular atrial fibrillation patients in a tertiary public hospital, Malaysia. J Pharm Pract Res 2020;50:406-12. [DOI: 10.1002/jppr.1647] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Brunetti ND, De Gennaro L, Tricarico L, Caldarola P. Budget impact analysis of PCSK9 inhibitors costs from a community payers' perspective in Apulia, Italy. Open Heart 2019;6:e001018. [PMID: 31413843 DOI: 10.1136/openhrt-2019-001018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]